64 related articles for article (PubMed ID: 17200332)
1. Targeting Fanconi anemia/BRCA2 pathway defects in cancer: the significance of preclinical pharmacogenomic models.
Gallmeier E; Kern SE
Clin Cancer Res; 2007 Jan; 13(1):4-10. PubMed ID: 17200332
[TBL] [Abstract][Full Text] [Related]
2. Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options.
Gallmeier E; Calhoun ES; Rago C; Brody JR; Cunningham SC; Hucl T; Gorospe M; Kohli M; Lengauer C; Kern SE
Gastroenterology; 2006 Jun; 130(7):2145-54. PubMed ID: 16762635
[TBL] [Abstract][Full Text] [Related]
3. Differential expression of TP53 associated genes in Fanconi anemia cells after mitomycin C and hydroxyurea treatment.
Martinez A; Hinz JM; Gómez L; Molina B; Acuña H; Jones IM; Frias S; Coleman MA
Mutat Res; 2008 Oct; 656(1-2):1-7. PubMed ID: 18647660
[TBL] [Abstract][Full Text] [Related]
4. High-throughput screening identifies novel agents eliciting hypersensitivity in Fanconi pathway-deficient cancer cells.
Gallmeier E; Hucl T; Brody JR; Dezentje DA; Tahir K; Kasparkova J; Brabec V; Bachman KE; Kern SE
Cancer Res; 2007 Mar; 67(5):2169-77. PubMed ID: 17332347
[TBL] [Abstract][Full Text] [Related]
5. [Fanconi anemia: cellular and molecular features].
Macé G; Briot D; Guervilly JH; Rosselli F
Pathol Biol (Paris); 2007 Feb; 55(1):19-28. PubMed ID: 16904272
[TBL] [Abstract][Full Text] [Related]
6. Fancm-deficient mice reveal unique features of Fanconi anemia complementation group M.
Bakker ST; van de Vrugt HJ; Rooimans MA; Oostra AB; Steltenpool J; Delzenne-Goette E; van der Wal A; van der Valk M; Joenje H; te Riele H; de Winter JP
Hum Mol Genet; 2009 Sep; 18(18):3484-95. PubMed ID: 19561169
[TBL] [Abstract][Full Text] [Related]
7. Human Mus81 and FANCB independently contribute to repair of DNA damage during replication.
Nomura Y; Adachi N; Koyama H
Genes Cells; 2007 Oct; 12(10):1111-22. PubMed ID: 17903171
[TBL] [Abstract][Full Text] [Related]
8. FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3.
Wilson JB; Yamamoto K; Marriott AS; Hussain S; Sung P; Hoatlin ME; Mathew CG; Takata M; Thompson LH; Kupfer GM; Jones NJ
Oncogene; 2008 Jun; 27(26):3641-52. PubMed ID: 18212739
[TBL] [Abstract][Full Text] [Related]
9. In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor.
van der Heijden MS; Brody JR; Dezentje DA; Gallmeier E; Cunningham SC; Swartz MJ; DeMarzo AM; Offerhaus GJ; Isacoff WH; Hruban RH; Kern SE
Clin Cancer Res; 2005 Oct; 11(20):7508-15. PubMed ID: 16243825
[TBL] [Abstract][Full Text] [Related]
10. The genetic and molecular basis of Fanconi anemia.
de Winter JP; Joenje H
Mutat Res; 2009 Jul; 668(1-2):11-9. PubMed ID: 19061902
[TBL] [Abstract][Full Text] [Related]
11. Deficiency in incisions produced by XPF at the site of a DNA interstrand cross-link in Fanconi anemia cells.
Kumaresan KR; Sridharan DM; McMahon LW; Lambert MW
Biochemistry; 2007 Dec; 46(50):14359-68. PubMed ID: 18020456
[TBL] [Abstract][Full Text] [Related]
12. Disruption of the Fanconi anemia/BRCA pathway in sporadic cancer.
Lyakhovich A; Surralles J
Cancer Lett; 2006 Jan; 232(1):99-106. PubMed ID: 16246487
[TBL] [Abstract][Full Text] [Related]
13. Genetic subtyping of Fanconi anemia by comprehensive mutation screening.
Ameziane N; Errami A; Léveillé F; Fontaine C; de Vries Y; van Spaendonk RM; de Winter JP; Pals G; Joenje H
Hum Mutat; 2008 Jan; 29(1):159-66. PubMed ID: 17924555
[TBL] [Abstract][Full Text] [Related]
14. The Fanconi anemia pathway: insights from somatic cell genetics using DT40 cell line.
Takata M; Ishiai M; Kitao H
Mutat Res; 2009 Jul; 668(1-2):92-102. PubMed ID: 19622405
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of Fanconi anemia genes in sporadic head and neck squamous cell carcinoma.
Wreesmann VB; Estilo C; Eisele DW; Singh B; Wang SJ
ORL J Otorhinolaryngol Relat Spec; 2007; 69(4):218-25. PubMed ID: 17409780
[TBL] [Abstract][Full Text] [Related]
16. Genotype-phenotype correlations in Fanconi anemia.
Neveling K; Endt D; Hoehn H; Schindler D
Mutat Res; 2009 Jul; 668(1-2):73-91. PubMed ID: 19464302
[TBL] [Abstract][Full Text] [Related]
17. Disruption of the FA/BRCA pathway in bladder cancer.
Neveling K; Kalb R; Florl AR; Herterich S; Friedl R; Hoehn H; Hader C; Hartmann FH; Nanda I; Steinlein C; Schmid M; Tonnies H; Hurst CD; Knowles MA; Hanenberg H; Schulz WA; Schindler D
Cytogenet Genome Res; 2007; 118(2-4):166-76. PubMed ID: 18000367
[TBL] [Abstract][Full Text] [Related]
18. Microarray mRNA expression analysis of Fanconi anemia fibroblasts.
Galetzka D; Weis E; Rittner G; Schindler D; Haaf T
Cytogenet Genome Res; 2008; 121(1):10-3. PubMed ID: 18544920
[TBL] [Abstract][Full Text] [Related]
19. Fanconi anemia: genetic analysis of a human disease using chicken system.
Takata M; Kitao H; Ishiai M
Cytogenet Genome Res; 2007; 117(1-4):346-51. PubMed ID: 17675877
[TBL] [Abstract][Full Text] [Related]
20. The Fanconi family adds a fraternal twin.
Grompe M; van de Vrugt H
Dev Cell; 2007 May; 12(5):661-2. PubMed ID: 17488615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
